Intracranial administration of CAR-T cells targeting IL13Rα2, a monomeric high-affinity receptor for IL-13 found to be overexpressed in glioblastomas [216], improves T-cell persistence and antitumor efficacy against glioblastoma [217, 218]. Here, IL13RA2 is linked to glioblastoma.